Because of this, additional quantitative and sensitive tests, such as RT-qPCR and western blotting analysis, were utilized to validate the higher levels of the DLX3 expression in preeclampsia-complicated placentae in contrast with gestational-matched control subjects. The gene discussed is DLX3; the disease is preeclampsia.